VANCOUVER, Sept. 18 /CNW/ - Protox Therapeutics Inc. (TSX-V:PRX) today announced the appointment of Dr. Martin Gleave MD, FRCSC, FACS, as the Chairman of its Clinical Advisory Board (Urology). Dr. Gleave brings to Protox a wealth of clinical and research experience in the field of prostate disease and will be instrumental in providing strategic guidance as the company advances its clinical programs for both localized prostate cancer and BPH (enlarged prostate).
